Nipocalimab Shows Significant Improvement in Systemic Lupus Erythematosus
The anti-neonatal Fc receptor (FcRn) monoclonal antibody nipocalimab demonstrated significant clinical improvement in patients with moderate-to-severe systemic lupus erythematosus (SLE) compared to a placebo, according to data presented at the EULAR 2026 Congress. Researchers reported that the 15 mg/kg dose of the drug, developed by Johnson & Johnson, showed efficacy at both 24 and 52 weeks of treatment.
Clinical Trial Results and Methodology
In the phase 2 JASMINE-SLE trial, 228 participants were randomized to receive either 5 mg/kg of nipocalimab, 15 mg/kg of the drug, or a placebo. The primary outcome was the Systemic Lupus Responder Index (SRI)-4 composite response at 24 weeks. Richard A. Furie, MD, of Northwell Health, reported that 53.5% of participants in the 15 mg/kg group met the primary endpoint, compared with 46.7% in the placebo group.
At 52 weeks, patients receiving the 15 mg/kg dose continued to show improvement, with 53.6% achieving an SRI-4 response, compared with 39.7% for the placebo arm. Additionally, 37.5% of the high-dose group reached a Lupus Low Disease Activity State (LLDAS), versus 20.5% in the placebo group. Furie noted that while the 15 mg/kg results were statistically significant, the lower 5 mg/kg dose did not reach statistical significance against the placebo.
Did You Know?
The JASMINE-SLE trial utilized a predetermined alpha of 10% for its primary endpoint analysis, rather than the traditional 5% threshold, reflecting its nature as a proof-of-concept study.
Mechanism of Action and Biomarker Subgroups
Nipocalimab functions by blocking the interaction of IgG with the neonatal Fc receptor. According to Furie, this process reduces circulating IgG, including pathogenic autoantibodies and immune complexes that contribute to cellular cytotoxicity and inflammation in lupus patients. The researchers analyzed three specific biomarker-based populations: those with autoantibodies, those with high autoantibody levels combined with low complement and high circulating immune complexes, and patients with high interferon gene signatures.
The 15 mg/kg dose showed robust results across these subgroups. For instance, in patients with high levels of autoantibodies, low complement, and high circulating immune complexes, 75.8% of those treated with the higher dose of nipocalimab achieved an SRI-4 response at 52 weeks, compared with 11.1% in the placebo group.
Expert Insight:
The data suggests that targeting the FcRn pathway provides a precise method for clearing pathogenic antibodies. By selectively reducing the IgG levels that drive inflammation in SLE, this therapeutic approach represents a shift toward more targeted immune modulation, though clinicians will be watching for long-term safety profiles as phase 3 trials proceed.
Future Outlook for Nipocalimab
Adverse events, including infusion reactions and sepsis, were reported as balanced across all treatment groups during the JASMINE-SLE trial. Given the outcomes, the phase 3 clinical program, named Gardenia, has already been initiated to further evaluate the drug’s performance in larger patient populations.
Frequently Asked Questions
What was the primary outcome of the JASMINE-SLE trial?
The primary outcome was the SRI-4 composite response at 24 weeks, which 53.5% of the 15 mg/kg nipocalimab group achieved compared to 46.7% of the placebo group.
How does nipocalimab work in patients with lupus?
Nipocalimab is an anti-neonatal Fc receptor monoclonal antibody that reduces circulating IgG, including pathogenic autoantibodies and immune complexes, by blocking their interaction with the Fc receptor.
What is the next step for this research?
The phase 3 clinical program, known as the Gardenia study, is currently underway to build upon the findings from the phase 2 JASMINE-SLE trial.
How might the results of the upcoming Gardenia trial influence current treatment protocols for moderate-to-severe lupus?